Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes (T2D): Outcomes by Body Mass Index (BMI)

被引：0
|
作者：
Shatskov, Alla
Rezvani, Geoffrey
Mansfield, Traci
机构：
来源：
DIABETES | 2016年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1141-P
引用
收藏
页码：A299 / A299
页数：1
相关论文
共 50 条
  • [21] Gastric bypass for the treatment of type 2 diabetes mellitus (T2DM) in patients with body mass index (BMI) below 35
    Wilson, Camilo
    Escalona, Alex
    Munoz, Rodrigo
    Perez, Gustavo
    Crovari, Fernando
    Guzman, Sergio
    Ibanez, Luis
    OBESITY SURGERY, 2007, 17 (08) : 1041 - 1041
  • [22] Sex Differences in Insulin Dose and Postprandial Glucose (PPG) as BMI Increases in Patients with Type 2 Diabetes (T2D)
    Jovanovic, Lois
    Heilmann, Cory R.
    Lewis, Michelle S.
    Lacaya, Lyndon B.
    Peters, Anne L.
    Jackson, Jeffrey A.
    DIABETES, 2009, 58 : A157 - A157
  • [23] Sex differences in insulin dose and postprandial glucose (PPG) as BMI increases in patients with type 2 diabetes (T2D)
    Jovanovic, L.
    Heilmann, C. R.
    Lewis, M. S.
    Lacaya, L. B.
    Peters, A. L.
    Jackson, J. A.
    DIABETOLOGIA, 2009, 52 : S356 - S357
  • [24] Changes in Beta-Cell Function during Dapagliflozin Therapy in Combination with Exenatide in Type 2 Diabetes Patients (T2D)
    Defronzo, Ralph A.
    Baskoy, Gozde
    Triplitt, Curtis L.
    Cersosimo, Eugenio
    Solis-Herrera, Carolina
    Adams, John M., II
    Hansis-Diarte, Andrea A.
    Gastaldelli, Amalia
    Chavez, Alberto
    DIABETES, 2024, 73
  • [25] Safety and Efficacy of Linagliptin and Basal Insulin Combination Therapy in Elderly Patients (age ≥70 years) with Type 2 Diabetes (T2D)
    Woerle, H. J.
    Neubacher, D.
    Patel, S.
    von Eynatten, M.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2013, 61 : S31 - S32
  • [26] Dapagliflozin and cardiovascular outcomes in patients with Type 2 diabetes
    Al-Bazz, Dalai Y.
    Wilding, John P. H.
    FUTURE CARDIOLOGY, 2020, 16 (02) : 77 - 88
  • [27] Cardiovascular Outcomes with Dapagliflozin for Patients with Type 2 Diabetes
    Pavlicek, Vojtech
    DIABETOLOGE, 2019, 15 (03): : 262 - 264
  • [28] EFFECTS OF DAPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES ACROSS BODY MASS INDEX CATEGORIES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN THE DECLARE TIMI 58 TRIAL
    Oyama, Kazuma
    Raz, Itamar
    Cahn, Avivit
    Kuder, Julia
    Murphy, Sabina
    Bhatt, Deepak
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John
    Park, Kyong-Soo
    Goudev, Assen
    Diaz, Rafael
    Spinar, Jindrich
    Gause-Nilsson, Ingrid
    Mosenzon, Ofri
    Sabatine, Marc
    Wiviott, Stephen D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 660 - 660
  • [29] Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patients
    Cersosimo, Eugenio
    YueJuan, Qin
    Baskoy, Gozde
    Chavez, Alberto
    Barkhordarian, Maryam
    Hansis-Diarte, Andrea
    Triplitt, Curtis
    DeFronzo, Ralph A.
    DIABETES OBESITY & METABOLISM, 2025, 27 (02): : 944 - 952
  • [30] THE EFFICACY AND RENAL SAFETY OF SWITCHING FROM DAPAGLIFLOZIN TO EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES
    Yang, Ai-Yu
    Chen, Hung-Chun
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 1374 - 1374
12345